Greenland Mines Ltd.
GRML
NASDAQ·Basic Materials·Other Precious Metals·Mkt cap $14.2M
$4.71
▲ +5.13%
P/E
-26.30
Mkt Cap
$14.2M
52-Wk Range
$0.16–$9.71
52-Week Range
$0.16 - $9.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 57.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cell and gene therapy technology platforms
- Specialized expertise in neurodegenerative disease treatment
- Experienced leadership and scientific team
- Early-stage market positioning in emerging therapeutic modalities
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
No forward estimates available
Increasing prevalence of neurodegenerative diseases globally
Value
Valuation data unavailable
Momentum
Falling
-69.6% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying GRML right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 17, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.03.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GRML stacks vs Other Precious Metals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related